Biotie Therapies Inc. clinical trials

Acquired by Acorda Therapeutics, Apr 11, 2016 · source ↗

The registry lists 13 studies whose lead sponsor is Biotie Therapies Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 3, 2019.

Studies

Recruiting first, then most recently updated. Showing 13 of 13. All Acorda Therapeutics studies →

• Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.TerminatedNCT03051607Phase 3

  Sponsor listed in the registry: Biotie Therapies Inc. · First submitted after Biotie Therapies Inc. became part of Acorda Therapeutics

• SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)CompletedNCT02258152Phase 2

  Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics

• Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's PatientsTerminatedNCT02453386Phase 3

  Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics

• Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)CompletedNCT00595231Phase 2

  Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics

• Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing OffCompletedNCT01283594Phase 2/3

  Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics

• Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent VolunteersCompletedNCT00656357Phase 1/2

  Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics

• A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug UsersTerminatedNCT03200080Phase 1

  Sponsor listed in the registry: Biotie Therapies Inc. · First submitted after Biotie Therapies Inc. became part of Acorda Therapeutics

• Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of TozadenantTerminatedNCT03212313Phase 1

  Sponsor listed in the registry: Biotie Therapies Inc. · First submitted after Biotie Therapies Inc. became part of Acorda Therapeutics

• Study to Evaluate SYN115 in Parkinson's DiseaseCompletedNCT00605553Phase 2

  Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics

• Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled TozadenantCompletedNCT02240290Phase 1

  Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics

• BTT-1023 in Rheumatoid ArthritisCompletedNCT00851240Phase 1

  Sponsor listed in the registry: Biotie Therapies Corp. · First submitted before Biotie Therapies Corp. became part of Acorda Therapeutics

• Safety and Pharmacokinetics of ELB353 in Healthy MenCompletedNCT00977886Phase 1

  Sponsor listed in the registry: Biotie Therapies Corp. · First submitted before Biotie Therapies Corp. became part of Acorda Therapeutics

• BTT1023 in PsoriasisCompletedNCT00871598Phase 1

  Sponsor listed in the registry: Biotie Therapies Corp. · First submitted before Biotie Therapies Corp. became part of Acorda Therapeutics